Companies

Lung-on-chip developer listed by market analysts as a key organ-on-chip player.

QSP modeling services and platform.

Acquired

Trains liver toxicity models on high-content imaging of primary human hepatocytes across 100,000+ compounds.

Seed · $15M disclosed

Instrument maker for live-cell functional assays used with organoid and organ-on-chip models.

Supplier of human iPSC-derived cells for research and drug discovery.

Nerve-on-a-chip and brain organoid models for neurotoxicity and neurology programs.

Series A · $6.8M disclosed

Barcelona supplier of ethically sourced human tissues and primary cells, known for primary liver cells used in ADME and toxicology work.

Acquired

Bioconvergence group (bioprinting and lab automation) that sold MatTek and Visikol to Sartorius in 2025.

Public

Supplier of human biospecimens, primary cells and ADME-Tox products used to build in vitro models.

PE-owned

Scientific instruments group adding human tissue models to its multiomics and imaging portfolio.

Public

Dynamic organ-on-chip systems with built-in oxygen and pH sensing, focused on gut models.

Seed · $1M disclosed

Largest model-informed drug development vendor: Simcyp PBPK simulator, QSP and cheminformatics.

Public

Largest preclinical CRO, repositioning around NAMs through its Alternative Methods Advancement Project while keeping in vivo capacity.

Public

Cheminformatics platforms for in silico research, including Design Hub and JChem.

Acquired

PhysioMimix organ-on-a-chip systems and assays for efficacy, ADME and safety work.

Series B · $44.8M disclosed

Oncology CRO offering patient-derived organoids, PDX models, ex vivo tissue platforms and biomarker work.

AI and simulation platform for drug discovery, including ADMET-NOW prediction models.

Lausanne organoid technology company.

Acquired

Nonprofit engineering lab behind the PREDICT96 high-throughput microphysiological platform.

Nonprofit

Wyss Institute spinout selling Organ-Chips with the Zoe culture module and the higher-throughput AVA Emulation System.

Series C+ · $225M disclosed

Human-on-a-chip multi-organ systems, sold mainly as studies.

Organoid pioneer with a foundational patent estate and services from model generation to high-throughput screening. About 70 employees at acquisition.

Acquired

QSP modeling for oncology, immunology and autoimmune disease.

Acquired

ADMET prediction software (Compass) trained on a precompetitive data consortium; plans an AI-native CRO layer.

Series A · $29.3M disclosed

3D microtissue models, assay services and the AkuraFlow microphysiological system for safety and efficacy testing.

Software and services for nonclinical study management and in silico toxicology.

PE-owned

Global CRO and data company that agreed to buy Charles River's in vitro discovery sites (Feb 2026).

Public

UK organ-on-chip and perfusion culture company.

Seed · $0.9M disclosed

Human cell-based microtissues and 3D models, plus Visikol. Sites in Ashland, MA and Bratislava, Slovakia; 80+ employees.

Acquired

Seoul-based developer of MEPS-X human microphysiological systems for toxicity and efficacy testing; also sells lipid nanoparticle manufacturing systems.

Series C+

Life science tools business that added organoid models and services by buying HUB.

Public

Leiden University spinout. OrganoPlate microfluidic tissue cultures in a standard plate format, plus ready-made models, instruments and contract research. About 100 employees.

Acquired

Human iPSC-derived cell models and assay services; ranked among top organoid research model companies by Tracxn.

Compartmentalized microfluidic neuro and skin organ-on-chip devices.

Series A · $8.9M disclosed

UK developer of human cell and organoid-based assay models.

Series B · $14.4M disclosed

Kidney and vascular organ-on-chip developer, renamed Numa Biosciences before its sale.

Acquired

Human lymph node immune organoids, scaled with robotics and AI, to model immune response across donor populations.

Series A · $30M disclosed

NGS-based viral safety testing for biologics, replacing animal-based adventitious agent tests.

Acquired

High-content imaging and phenotypic assay services, including cell painting and neurotoxicity work.

Acquired

Automated tissue foundry that grows donor-defined human micro-tissues and trains AI models of tissue response, pitched as a verification layer for AI biology.

Seed · $20M disclosed

University of Arizona spinout pairing patient-derived organoids with an AI platform for drug screening, preclinical safety and patient profiling.

Seed · $3.5M disclosed

Bio-AI platform that trains clinical safety prediction models on stem cell-derived patients-on-a-chip.

Seed · $37M disclosed

Yale-linked company running Human Data Trials on donated, non-transplantable human organs kept functional by perfusion.

Seed · $19.5M disclosed

Lab and bioprocess supplier that bought MatTek to add 3D microtissues to its cell analysis line.

Public

Modeling and simulation software and services, including DILIsym quantitative systems toxicology.

Public

Microfluidic tissue model developer listed by market analysts as a key organ-on-chip player.

TU Berlin spinout building Multi-Organ-Chip systems that link several human tissues in one circuit.

Developer of ReproTracker, a human stem cell-based in vitro assay that complements developmental and reproductive toxicity testing.

Penn spinout that grows 20+ human tissue types on a robotic platform and trains AI models on the results.

Series A · $78M disclosed

Repositioned in Apr 2025 to sell liver and intestinal toxicology services on donor-derived 3D tissue models.

Public

Closed-loop platform combining human organ-on-chip models, lab automation, high-content imaging, multi-omics and AI.

Series A · $50M disclosed